https://www.selleckchem.com/products/bi-2493.html
Meanwhile, only grade 1 cytokine release syndrome (CRS) was observed. This case report demonstrated that BCMA CAR-T could effectively eradicate CNS-involved MM with low adverse events, suggesting that CAR-T cell therapy could be a feasible therapeutic option for this kind of refractory disease. https//ClinicalTrials.gov, identifier NCT04537442.a. https//ClinicalTrials.gov, identifier NCT04537442.a. This study investigated the high-risk factors associated with the increased vulnerability for subsequent clinical CR-GNB infection in carbap
Like
Comment
Share
